Premium
Therapy‐related classical H odgkin lymphoma after a primary haematological malignancy: a report on 13 cases
Author(s) -
Cheminant Morgane,
Galicier Lionel,
Brière Josette,
Boutboul David,
Micléa JeanMichel,
Ve MarieDominique,
Robin Marie,
Thieblemont Catherine,
Brice Pauline
Publication year - 2012
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2012.09202.x
Subject(s) - medicine , lymphoma , malignancy , chemotherapy , monoclonal antibody , disease , hematology , oncology , immunology , antibody , gastroenterology
Summary The risk of developing Hodgkin lymphoma ( HL ) is increased in immunodeficiencies or during the treatment of some autoimmune diseases. The development of new therapeutic agents has highlighted the risk of unusual lymphoid proliferations, particularly classical HL (c HL ). We report the clinicopathological findings of 13 c HL arising in patients treated for a primary haematological malignancy. Eight patients had received an immunomodulator, protein tyrosine‐kinase inhibitor or monoclonal antibody, which may have contributed to the c HL development. Most patients had disseminated disease with poor prognostic factors at cHL diagnosis. Despite the initial presentation, good outcomes were achieved with standard c HL chemotherapy.